Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV002312397 | SCV000846711 | uncertain significance | Inborn genetic diseases | 2016-07-08 | criteria provided, single submitter | clinical testing | The p.G1177S variant (also known as c.3529G>A), located in coding exon 29 of the ATP13A2 gene, results from a G to A substitution at nucleotide position 3529. The glycine at codon 1177 is replaced by serine, an amino acid with similar properties. This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV000878446 | SCV001021355 | benign | Kufor-Rakeb syndrome; Autosomal recessive spastic paraplegia type 78 | 2024-12-04 | criteria provided, single submitter | clinical testing | |
Gene |
RCV002279497 | SCV002567553 | likely benign | not provided | 2020-10-21 | criteria provided, single submitter | clinical testing | See Variant Classification Assertion Criteria. |
Prevention |
RCV004547892 | SCV004788827 | likely benign | ATP13A2-related disorder | 2020-10-13 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |